Showing results (1131-1140 of 1,508) with videos related to

Sort By:
Pageof 151
ESC Heart Failure|December 11, 2020
Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodellingKieran F Docherty, Ross T Campbell, Katriona J M Brooksbank, et al.
European Journal of Heart Failure|January 10, 2025
Cardiovascular magnetic resonance-estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction and dysglycaemia (SUGAR-DM-HF)Joanna Osmanska, Kieran F Docherty, Colin Berry, et al.
Frontiers in Public Health|May 7, 2024
Exploring patterns in mental health treatment and interests of single adults in the United States: a secondary data analysisAmanda N Gesselman, Ellen M Kaufman, Lee Y S Weeks, et al.
Plos One|March 11, 2014
Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activityMarisa O Peluso, Veronica T Campbell, Joseph A Harari, et al.
ESC Heart Failure|March 12, 2021
Sex differences in congestive markers in patients hospitalized for acute heart failureCaroline Espersen, Ross T Campbell, Brian Claggett, et al.
Circulation. Heart Failure|September 13, 2022
Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population CohortPaul Welsh, Ross T Campbell, Leanne Mooney, et al.
Urologic Oncology|July 24, 2021
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinomaAlberto C Pieretti, Mary E Westerman, Alexandria Childs, et al.
Neuroimage. Clinical|July 6, 2022
Sensitivity of portable low-field magnetic resonance imaging for multiple sclerosis lesionsT Campbell Arnold, Danni Tu, Serhat V Okar, et al.
Neurocritical Care|September 5, 2024
Development of a Quality Indicator Set for the Optimal Acute Management of Moderate to Severe Traumatic Brain Injury in the Australian ContextToby Jeffcote, Camila R Battistuzzo, Rebecca Roach, et al.
The Oncologist|April 11, 2025
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCCAndrew W Hahn, Nabil Adra, Ulka Vaishampayan, et al.
Pageof 151